G-CSF Linked With Some Reduction in Neutropenia-related Hospitalization

Share this content:
Primary G-CSF was associated with low-to-modest benefit in lowering risk for neutropenia-related hospitalization.
Primary G-CSF was associated with low-to-modest benefit in lowering risk for neutropenia-related hospitalization.

Among patients with breast cancer who received docetaxel and cyclophosphamide (TC), or docetaxel, carboplatin, and trastuzumab (TCH) regimens, primary granulocyte colony-stimulating factor (G-CSF) was associated with low-to-modest benefit in lowering risk for neutropenia-related hospitalization, according to a study published in the Journal of Clinical Oncology.1

In a retrospective analysis, researchers led by Abiy Agiro, PhD, examined data from 8745 patients who were at least 18 years of age to determine outcomes after G-CSF prophylaxis with risk for neutropenia-related hospitalization. In total, 4815 received TC, 2292 received TCH, and 1638 received conventional-dose doxorubicin and cyclophosphamide (AC).

Primary prophylaxis, which was defined as G-CSF administration within 5 days of chemotherapy initiation, was associated with a reduced risk of neutropenia-related hospitalization for TC and TCH, but not AC.

RELATED: Breast Cancer Risk and Psychosocial Adjustment Among Adolescents

Twenty patients would have to be treated for 21 days with the TC regimen to avoid 1 neutropenia-related hospitalization, while 18 patients would have to be treated with the TCH regimen to avoid 1 neutropenia-related hospitalization.

Reference

  1. Agiro A, Ma Q, Acheson AK, et al. Risk of neutropenia-related hospitalization in patients who received colony-stimulating factors with chemotherapy for breast cancer. J Clin Oncol. 2016 Sep 19. doi: 10.1200/JCO.2016.67.2899 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters